- Autologous Hematopoietic Stem Cells
- Autologous Disc Chondrocytes
- Autologous Mesenchymal Stem Cells
- Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells
- Gene Therapy
- Others
Degenerative Disc Disease Therapeutics Market size was valued at USD 1,844.7 million in 2022 and is anticipated to grow at a CAGR of 9.6 % over 2023-2029. Degenerative disc disease (DDD) is a common age-related condition that affects the intervertebral discs in the spine, causing them to degenerate, lose flexibility, and potentially lead to pain and functional limitations. While it is often considered a natural part of the aging process, therapeutic approaches are used to alleviate pain and discomfort, improve spinal function, and enhance the patient's overall quality of life. The rising incidence of spinal disorders plays a pivotal role in driving the revenues of the degenerative disc disease therapeutics market. As the prevalence of spinal disorders, including DDD, continues to increase globally, there is a growing demand for effective therapeutic solutions to alleviate pain and improve the quality of life for affected individuals. Factors such as sedentary lifestyles, physical trauma, and the aging population contribute to the higher incidence of spinal issues. Consequently, more individuals seek diagnosis and treatment for DDD-related symptoms, leading to increased market demand for therapeutic interventions, including medications, physical therapy, minimally invasive procedures, and surgical options.
Moreover, increased sedentary lifestyles are a significant driver behind the growth of the degenerative disc disease (DDD) therapeutics market. Modern lifestyles characterized by prolonged periods of sitting, whether due to desk jobs, extended screen time, or reduced physical activity, contribute significantly to the development and exacerbation of DDD. As more individuals lead sedentary lives, they become more susceptible to spinal issues, including disc degeneration. This trend fuels the demand for DDD therapeutics as affected individuals seek relief from pain and discomfort. However, stringent regulations, lack of adequate awareness about the disease, and high cost of treatment are hindering the degenerative disc disease therapeutics market growth. Meanwhile, the rise in the geriatric population, technological developments, and growing healthcare expenditure worldwide are anticipated to contribute to the growth of the market. Key market players are doing research and developing innovative treatment options to satisfy the demand from the medical industry. For instance, in January 2023, DiscGenics, Inc. received FDA approval for Injectable Disc Cell Therapy (IDCT), which is an allogeneic discogenic progenitor cell therapy that can be injected to treat symptomatic lumbar degenerative disc disease (DDD).
Study Period
2024-2030Base Year
2023CAGR
9.6%Largest Market
North AmericaFastest Growing Market
North America
With rising prevalence of spine issues, degenerative disc disease therapeutics market anticipated to grow at significant rate over the forecast period. In addition, rise in geriatric population and technological developments, improved government funding, projected to drive the growth of degenerative disc disease therapeutics market over forecast period. However, stringent regulations, lack of adequate awareness about disease, and the stringent regulatory framework are hindering the degenerative disc disease therapeutics market growth.
By Therapy
By Distribution Channel
By Geography
The degenerative disc disease therapeutics market size was valued at USD 1,844.7 Million in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The growing prevalence of chronic pain, the increasing aging population, and government initiatives and healthcare policies that promote healthcare access and support research and development in the field of spine care and DDD are some of the key opportunities for companies to enhance their revenue over the forecast years.
Ongoing advancements in medical technology, such as minimally invasive surgical techniques, regenerative therapies, and improved diagnostic tools stand out as a significant trend within the degenerative disc disease therapeutics market.
1.Executive Summary |
2.Global Degenerative Disc Disease Therapeutics Market Introduction |
2.1.Global Degenerative Disc Disease Therapeutics Market - Taxonomy |
2.2.Global Degenerative Disc Disease Therapeutics Market - Definitions |
2.2.1.Product Type |
2.2.2. Service |
2.2.3.Region |
3.Global Degenerative Disc Disease Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Degenerative Disc Disease Therapeutics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Degenerative Disc Disease Therapeutics Market By Product Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Autologous Hematopoietic Stem Cells |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Autologous Disc Chondrocytes |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Autologous Mesenchymal Stem Cells |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Gene Therapy |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Degenerative Disc Disease Therapeutics Market By Service, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital Pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Online Pharmacies |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Retail Pharmacies |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Degenerative Disc Disease Therapeutics Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Degenerative Disc Disease Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Autologous Hematopoietic Stem Cells |
8.1.2.Autologous Disc Chondrocytes |
8.1.3.Autologous Mesenchymal Stem Cells |
8.1.4.Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
8.1.5.Gene Therapy |
8.1.6.Others |
8.2. Service Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital Pharmacies |
8.2.2.Online Pharmacies |
8.2.3.Retail Pharmacies |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Degenerative Disc Disease Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Autologous Hematopoietic Stem Cells |
9.1.2.Autologous Disc Chondrocytes |
9.1.3.Autologous Mesenchymal Stem Cells |
9.1.4.Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
9.1.5.Gene Therapy |
9.1.6.Others |
9.2. Service Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacies |
9.2.2.Online Pharmacies |
9.2.3.Retail Pharmacies |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) Degenerative Disc Disease Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Autologous Hematopoietic Stem Cells |
10.1.2.Autologous Disc Chondrocytes |
10.1.3.Autologous Mesenchymal Stem Cells |
10.1.4.Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
10.1.5.Gene Therapy |
10.1.6.Others |
10.2. Service Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacies |
10.2.2.Online Pharmacies |
10.2.3.Retail Pharmacies |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Degenerative Disc Disease Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Autologous Hematopoietic Stem Cells |
11.1.2.Autologous Disc Chondrocytes |
11.1.3.Autologous Mesenchymal Stem Cells |
11.1.4.Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
11.1.5.Gene Therapy |
11.1.6.Others |
11.2. Service Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacies |
11.2.2.Online Pharmacies |
11.2.3.Retail Pharmacies |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Degenerative Disc Disease Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Autologous Hematopoietic Stem Cells |
12.1.2.Autologous Disc Chondrocytes |
12.1.3.Autologous Mesenchymal Stem Cells |
12.1.4.Autologous Bone Marrow Aspirate/Bone Marrow Concentrated Cells |
12.1.5.Gene Therapy |
12.1.6.Others |
12.2. Service Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacies |
12.2.2.Online Pharmacies |
12.2.3.Retail Pharmacies |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.AnGes MG Inc (Japan) |
13.2.2.Biopharm GmbH (Germany) |
13.2.3.BioRestorative Therapies Inc (US) |
13.2.4.Bone Therapeutics SA (Belgium) |
13.2.5.DiscGenics Inc (US) |
13.2.6.Samumed LLC (US) |
14. Research Methodology |
15. Appendix and Abbreviations |